Jump to content

User:Martin A White/sandbox

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Martin A White (talk | contribs) at 10:47, 1 June 2014. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Lactobacillus bulgaricus GLB44
Scientific classification
Kingdom:
Bacteria
Division:
Firmicutes
Class:
Bacilli
Order:
Lactobacillales
Family:
Lactobacillaceae
Genus:
Lactobacillus
Species:
L. delbrueckii
Subspecies:
L. d. bulgaricus

GLB44 is a member of the Lactobacillus delbrueckii subsp. bulgaricus group of probiotic (“beneficial bacteria”), found originally in traditional European yogurts.[1] GLB44 is the only known L. bulgaricus of vegan origin available as a commercial probiotic. Probiotics are health promoting bacteria[2] that should be taken regularly to support healthy digestive[3] and immune systems[4], but also during antibiotic treatment[5] to alleviate the symptoms of antibiotic-associated diarrhea.[5] Probiotics can also be used preventatively before travel to decrease the risk of traveler’s diarrhea.[6] Different strains of good bacteria have very different characteristics and effectiveness. Lactobacillus bulgaricus GLB44 has been discovered on Galanthus nivalis (snowdrop flower) in Bulgaria.[1] The natural habitat of the snowdrop flower are European mountainous regions.[7] Thus, GLB44 is capable of surviving in freezing temperatures, in a 100% plant environment, as the snowdrop flowers between January and May in nature[8], when the temperatures can fall below freezing in this region.[8] These characteristics of its natural habitat allows for GLB44 to survive in foods that are plant based and remain unaffected when stored in the refrigerator.

GLB44 has inhibitory qualities against bad bacteria such as E. Coli and Salmonella spp.[9] A research study was completed by a Harvard Medical School Professor at Brigham and Women's Hospital, Andrew B. Onderdonk, PhD.[10] The study has revealed GLB44’s strength and effectiveness against bacterial pathogens.[9] GLB44 has patent pending status in the US for its pathogen inhibitory qualities in vegan foods.

File:Snowdrop flower Vitosha.jpg
Fig 1: galanthus nivalis
File:Galanthus nivalis distribution map EU.png
Fig 2. Areas in yellow show the galanthus nivalis distribution [8]

All other commercially available strains of L. bulgaricus are isolated from traditional yogurts and are grown in milk.[11] Distinctly from the other L. bulgaricus, GLB44 grows very well in vegetable juices, given its natural plant habitat.[9] Since all probiotics carry some of the organic matter in which they are grown, GLB44 carries only traces of vegetable juice only. GLB44 is currently grown in the European Union, in vegetable juice sourced from European farms that are GMO free.[12]

Sourced originally from the leaves of the snowdrop flower makes GLB44 very different from other probiotics such as L. plantarum 299v or L. rhamnosus GG which are originally extracted from the human mouth.[13] Others like Bifidobacterium are extracted from the feces of newborns14[14], while others such as some strains of L. brevis come from the human vaginal canal[15]. GLB44 does not have any interface with mammalian organs, only flower leaves and juice.[16] This is important for multiple reasons such as the fact that there is some scientific evidence that if a probiotic grows in the human mouth naturally it could accelerate tooth decay.[17]

Also many probiotics have major allergens in the growth solution which is another difference with GLB44 that has no major allergens as part of its growth medium [13],[18]. For example the growth medium for L. plantarum 299v includes barley that has small content of gluten[13], and L. rhamnosus GG has small content of casein[18]. The fact that GLB44 is grown in vegetable juice means GLB44 does not contain any of the seven major allergens for which the FDA requires additional labeling: lactose, gluten, soya, peanuts, tree nuts, fish or xrustacean shellfish.[19]

It is estimated that 30 to 50 million Americans have some degree of lactose intolerance. Certain populations are more affected than others, including 75% of African American, Jewish, Mexican and Native American, and 90% of Asian populations.[20] Thus, having probiotic bacteria such as GLB44 without any lactose is especially important for the lactose sensitive population.

Another major difference is the safety tract record of L. bulgaricus is now over 109 years since it was scientifically isolated.[16] Even well established probiotics such as L. rhamnosus and L. plantarum 299v have only a fraction of the safety record with 31 years and 21 years respectively.[21],[13] On the other hand, there are certain similarities between L. bulgaricus GLB44 and some of the other probiotics. For example L. bulgaricus, L. rhamnosus GG and L. plantarum 299v all have scientific records of their ability to pass successfully through the gastrointestinal tract [22],[23],[13]. Also they all have records to inhibit to a degree pathogenic bacteria.[9],[23],[13]

Finally, all three example probiotics in this comparison have all research tests performed by reputable academic professionals, for the case of GLB44, the research was performed by a Harvard Medical School[9] professor, for the case of L. rhamnosus GG by two Tufts University professors[23], and for L. plantarum 299v by a professor at the Lund University.[13] All three probiotics have commercial brand names in the United States. GLB44 is commercially available under the brand name ProViotic as a probiotic food supplement, L. rhamnosus GG as Culturelle, and L. plantarum 299v as the ingredient in GoodBelly.

History of Discovery: The bacillus of long life

Living in a mountain village of Bulgaria with her son who was 101 years old, baba Vasilka’s age was not unusual for her community, which, of note, consumed yogurt containing L. bulgaricus as a dietary staple.[24],[25]

The first L. bulgaricus was discovered more than a century ago, the result of a study into the unusual longevity of mountain villagers in Bulgaria (thus called L. bulgaricus) by Dr. Stamen Grigorov in 1905.[1] In 1912, the New York Times wrote an overview article about the new discovery and the use of fermented yogurts with L. bulgaricus in Bulgaria with the title “Metchnikoff Confirmed in His Theory of Long Life,” highlighting that the longest living person in the world was baba Vasilka, age 126.[24] In the article the author described the discovery as follows: “In Bulgaria, the home of this bacillus, the majority of the natives live to age considerably in excess of what is recognized as the term of life among Western nations, an inquiry has shown that in the Eastern part of Southern Europe, among a population of about 3,000,000, there were more than 3,000 centenarians found performing duties which would not be assigned to a man of 65 years of age elsewhere. It is quite common to find among the peasants who live to such a large extent upon soured milk individuals of 110 and 120 years of age.”

The article continues in the explanation of these facts: “Prof. Elie Metchnikoff gave to the world the result of his investigation on the subject of longevity in which he held that the chief enemy to long life in the human species the large intestine, or colon. This organ by becoming the breeding place for poisonous microbes, the fertile cause for the debility that comes with old age, and the death that cuts off many a career of normal course is not nearly run.” “Acids are the best antiseptics; they have been used from time immemorial as preservatives; pickles are persevered with vinegar, acidic acid, and when milk is allowed to sour under proper conditions, the germs of putrefaction are destroyed or their activity inhibited, and it keeps a considerable time. How can acids be applied so as to control the bacterial flora of the large intestine? Not in the ordinary way because, when administered through the mouth, they are used up long before they can penetrate the colon. The brilliant idea occurred to Prof. Metchnikoff of the administering acid-producing germs which might work their way through the digestive system, and, reaching the large intestine, produce the acid required. After much experimenting, the bacillus of Massol, Bacillus Bulgaricus was adopted as the most suitable.”

Since Metchnikoff, advances in science have uncovered that the process of pathogenic inhibition is more complex than simply increasing the acidity in the colon, as the probiotic bacteria produce bacteriocins, bacterial synthesized proteins that inhibit pathogenic bacteria.[26],[27] In the case of L. bulgaricus this bacteriocin is called bulgaricin [26]. Also there is a complex interplay between the probiotic bacteria and the body’s immune system in the large intestine, where the good bacteria stimulate the body’s own immune system to inhibit the pathogenic bacteria.[28] For example, in a controled study, 61 elderly volunteers, after 6 months of a daily dose of L. bulgaricus, responded to the intake of probiotic with an increase in the percentage of NK cells, an improvement in the parameters defining the immune risk profile (IRP), and an increase in the T cell subsets that are less differentiated. The probiotic group also showed decreased concentrations of the pro-inflammatory cytokine IL-8 but increased antimicrobial peptide hBD-2.[28]

Thus, the New York Times article uncovered the initial views of this new discovery and also the most telling fact of all: that in these Bulgarian communities there were 3,000 centenarians from a population of 3 million – six times higher than the number of centenarians per capita in the United States today.[29]

GLB44 Studies by Harvard Medical School Professor at Brigham and Women’s Hospital

Dr. Andrew Onderdonk, a Pathology Professor at Harvard Medical School and a Director of the Clinical Microbiology Laboratory at Brigham and Women’s hospital has published one of his research tests on the following website: www.glb44.org, where GLB44 is tested against bacterial pathogens such as Salmonella sp. and E. Coli. In his study, both Salmonella sp. and E. Coli are inhibited when mixed with GLB44 in vegetable juice.[9] The study confirms that GLB44 is a specific strain of the L. bulgaricus subspecies, and that its inhibitory power surpasses other L. bulgaricus strains.[9]

Summary of Scientific Studies that Have Researched Positive Effects of L. Bulgaricus on its Environment and the Human Body

These studies do not involve significant human trials sufficient for the US Food and Drug Administration to allow representative health claims[30], nevertheless, these studies, performed in reputable academic institutions, provide an insight on some of the properties of this bacteria:

1. The scientific study “In Vitro Cholesterol Uptake by Lactobacillus delbrueckii subsp. bulgaricus Isolates” performed at the University of Warsaw proved that L. bulgaricus has the ability to uptake cholesterol from its environment.[31]

2. Helicobacter pylori bacterial infection is associated with chronic gastritis, peptic ulcer disease, and gastric cancer. The scientific study “Anti-Helicobacter pylori activity of Lactobacillus delbrueckii subsp. bulgaricus strains” performed by the Medical University of Sofia concluded that all tested L. bulgaricus strains inhibited a number of H. pylori strains.[32]

3. In 2010, the British Journal of Nutrition reported a study that included fifty-seven elderly individuals (mean age 74) and eighty five healthy individuals (mean age 67), who consumed L. bulgaricus every day over 12 week period. The result of the study clearly showed that people who consumed L. bulgaricus daily had 2.6 times lower incidence of catching a cold.[4] The study concluded that the consumption of yogurt fermented with L. bulgaricus augmented natural killer cell activity and reduced the risk of catching the common cold in elderly individuals.

4. The Federal Research Centre for Nutrition in Germany reported that consuming L. bulgaricus on regular basis is associated with anticarcinogenic effects, one mechanism of which is the detoxification of genotoxins in the gut.[3] This mechanism was shown experimentally in animals with use of the rat colon carcinogen, with endpoints that ranging from tumorigenesis to induction of DNA damage.[3]

5. The Journal of Dairy Science reports that L. bulgaricus can act as a suppressant of allergic inflammation.[33] Allergic inflammation is an important pathophysiological feature of several disabilities or medical conditions including allergic asthma, atopic dermatitis, allergic rhinitis and several ocular allergic diseases.[34],[35],[36],[37]

6. Clostridium difficile is the most common cause of AAD, and the resulting C. difficile mediated infection (CDI) is potentially deadly.[38] C. difficile associated diarrhea (CDAD) is manifested by severe inflammation and colitis, mostly due to the release of two exotoxins by C. difficile that cause destruction of epithelial cells in the intestine.[38] The study “Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells“ demonstrates that L. bulgaricus can reduce the colonization of C. difficile cells in colorectal cells, and thus prevent Antibiotic Associated Diarrhea.

Safety of Use

Due to more than a century of safe use, the FDA has granted L. bulgaricus a “grandfather” status, with an automatic GRAS status (Generally Recognized as Safe).[39] Moreover, the Code of Federal Regulations mandates that in the US, for a product to be called “yogurt”, it must contain two specific strains of lactic acid bacteria: Lactobacillus bulgaricus and Streptococcus thermophilus, as regulated by the FDA[40].

Even as a direct supplement, L. bulgaricus has a track record of safe use for more than 60 years in the United States. For example, the supplement Lactinex with a different strain of L. bulgaricus has been marketed as a commercial product in the US market since 1952.[41] Despite not being vegan, and grown in milk, Lactinex shows a long history of L. bulgaricus as a food supplement in the United States.

For the last 100 years there has been not a case of overdose on probiotics[42], which substantiates L. bulgaricus GLB44 as an extremely safe product, without limitations of the quantity consumed. It is also recommendable for the elderly[4] as it helps reduce infections such as the common cold, as well as for young children (i.e. when they suffer from acute diarrhea[38]). Harvard Women’s Health Watch, published by Harvard Medical School, recommends a GLB44 dose range of between 1 to 10 billion colony forming units (CFU) per day, the amount contained in a capsule or two several days a week.[2]

GLB44 is not a bacteria that can live naturally in the human mouth, as presented by the Human Oral Microbiome Database.[43] A study conducted by the University of Texas uncovered that while a bacteria called S. mutans is the biggest culprit for tooth decay, various lactobacilli are also associated with the progression of lesions.[44] GLB44 does not increase the risk of tooth decay due to its inability to live in the human mouth[43], an advantage versus other probiotics that contain any of the following lactobacilli that live naturally in the human mouth and could contribute to the tooth decay: L. acidophilus,[43] L. brevis,[43] L. casei,[43] L. fermentum,[43] L. gasseri,[43] L. paracasei,[43] L plantarum,[43] L. reuteri,[43] L. rhamnosus,[43] L. salivarius[43]

L. bulgaricus GLB44 and the Definition of Probioitics

The Food and Drug Administration (FDA) has presented on their website the following guideline: “Guidance for Industry on Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration”[45] In this article, the definition of “Probiotics” is two fold: 1) live microbial food supplements that beneficially affect the host by improving its intestinal microbial; 2) live microorganisms which, when consumed in adequate amounts of food, confer a health benefit on the host.

Another guideline presented on the FDA website “Guidelines for Evaluation of Probiotics in Food”[46] has outlined more specific criteria for the definition of effective probiotic based on the following criteria:

  • Resistance to gastric acidity
  • Bile acid resistance
  • Adherence to mucus and/or human epithelial cells and cell lines
  • Antimicrobial activity against potentially pathogenic bacteria
  • Ability to reduce pathogen adhesion to surfaces
  • Bile salt hydrolase activity

Of note, the authors of this guideline specifically outline L. bulgaricus as an example of an effective probiotic with suitable scientific substantiation of health benefits[46].

Resistance to gastric acid and bile acid are scientifically presented in the following studies where L. bulgaricus successfully passes through the human intestinal tract, maintaining its viability: “Survival of Yogurt Bacteria in the Human Gut”[22] and “Lactobacillus delbrueckii subsp. bulgaricus Collection to select a strain able to survive to the human intestinal tract.”[47]. Adherence to mucus and human epithelial cells and cell lines and the ability to reduce pathogen adhesion to surfaces is scientifically proven by the research “Influence of Gastrointestinal System Conditions on Adhesion of xopolysaccharide-producing Lactobacillus delbrueckii subsp. bulgaricus strains to Caco-2 Cells”[48]

There are also numerous studies that outline the antimicrobial activity of L. bulgaricus against potentially pathogenic bacteria such as E. Coli[2], Salmonella sp.[2], S. aureus[2], V. cholera[2], B. subtilis[2], C. difficile[38] and others.

Thus, the L. bulgaricus meets all the criteria of the FDA probiotic guideline, with scientific evidence supporting the strain as the clearest example of a safe and effective probiotic food supplement.


  1. ^ a b c Michaylova, M (2007 Apr). "Isolation and characterization of Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus thermophilus from plants in Bulgaria". FEMS microbiology letters. 269 (1): 160–9. PMID 17257163. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  2. ^ a b c d e f g Harvard Women’s Health Watch (2005). "Benefit of Probiotics: Should you take a daily dose of bacteria?". from Harvard University Website. Retrieved 26 May 2014.
  3. ^ a b c Wollowski, I (2001 Feb). "Protective role of probiotics and prebiotics in colon cancer". The American journal of clinical nutrition. 73 (2 Suppl): 451S–455S. PMID 11157356. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  4. ^ a b c Makino, S (2010 Oct). "Reducing the risk of infection in the elderly by dietary intake of yoghurt fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1". The British journal of nutrition. 104 (7): 998–1006. PMID 20487575. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  5. ^ a b Beniwal, RS (2003 Oct). "A randomized trial of yogurt for prevention of antibiotic-associated diarrhea". Digestive diseases and sciences. 48 (10): 2077–82. PMID 14627358. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  6. ^ Black, F (1989). "Prophylactic Efficacy of Lactobacilli on Traveler's Diarrhea". Travel Medicine Proceedings of the First Conference on International Travel Medicine, Zürich, Switzerland, 5-8 April 1988. Berlin, Heidelberg: Springer Berlin Heidelberg. pp. 333–5. ISBN 978-3-642-73772-5. {{cite book}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ Peev D, Vladimirov V (2013). "Galanthus nivalis". Red Data Book of the Republic of Bulgaria. Institute of Biodiversity and Ecosystem Research – Bulgarian Academy of Science Electronic Database.
  8. ^ a b c Blasi A (2014). "E-taxonomy of the bulbous monocot genera listed in CITES: Galanthus and Sternbergia".,available on the electronic website: http://citesbulbs.myspecies.info/category/galanthus-wild-species/galanthus-alpinus
  9. ^ a b c d e f g Onderdonk A, Professor of Pathology at Harvard Medical School. "Scientific Test Result: www.glb44.org" (PDF). Clinical Microbiology Laboratory Brigham and Women’s Hospital.
  10. ^ Professional information for Professor Andrew Onderdonk is available on Channing Laboratory at Harvard Medical School website: http://www.channing.harvard.edu/onderdonk.htm
  11. ^ Miteva, V (1998 Mar). "Characterization of bacteriocins produced by strains from traditional Bulgarian dairy products". Systematic and applied microbiology. 21 (1): 151–61. PMID 9741120. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  12. ^ GMO Free Europe Conference (2012) Electronic Database: http://www.gmo-free-regions.org/gmo-free-regions/bulgaria.html
  13. ^ a b c d e f g Goran Moulin (2010) “Lactobacillus plantarum 299v” as available on the manufacturer website: http://probi.se/files/2009/07/LP299v-10.pdf
  14. ^ Bezirtzoglou, E (1990). "Occurrence of Bifidobacterium in the feces of newborns delivered by cesarean section". Biology of the neonate. 58 (5): 247–51. PMID 2076442. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  15. ^ Antonio, May A. D. "The Identification of Vaginal Species and the Demographic and Microbiologic Characteristics of Women Colonized by These Species". The Journal of Infectious Diseases. 180 (6): 1950–1956. doi:10.1086/315109. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); no-break space character in |coauthors= at position 15 (help); no-break space character in |first= at position 4 (help)
  16. ^ a b GLB44 patent pending status as reported on the branded product website: www.proviotic.com
  17. ^ Schwendicke, F. "Cariogenic Effects of Probiotic in a Dental Biofilm Model". Caries Research. 48 (3): 186–192. doi:10.1159/000355907. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  18. ^ a b Mark Hyman (2014) “The Health Living Store” as available on the website: http://store.drhyman.com/Store/Show/ListAlphabetically/378/Culturelle-with-Lactobacillus-GG
  19. ^ "Food Facts" (PDF). (June 2010). The US Food and Drug Administration Center for Food Safety. Retrieved 30 May 2014., Website Content: http://www.fda.gov/downloads/Food/ResourcesForYou/Consumers/UCM220117.pdf
  20. ^ WebMD medical reference website content: http://www.webmd.com/digestive-disorders/digestive-diseases-lactose-intolerance
  21. ^ Patent Search (2014) on the website: http://worldwide.espacenet.com/publicationDetails/biblio?CC=US&NR=4839281&KC=&FT=E&locale=en_EP
  22. ^ a b Elli, M. (4 July 2006). "Survival of Yogurt Bacteria in the Human Gut". Applied and Environmental Microbiology. 72 (7): 5113–5117. doi:10.1128/AEM.02950-05. PMID 16820518. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  23. ^ a b c Conway, P.L. (1987 Jan). "Survival of Lactic Acid Bacteria in the Human Stomach and Adhesion to Intestinal Cells". Journal of Dairy Science. 70 (1): 1–12. doi:10.3168/jds.S0022-0302(87)79974-3. PMID 3106442. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  24. ^ a b "Metchnikoff Confirmed In His Theory Of Long Life". The New York Times. January 21, 1912. Retrieved 30 May 2014.
  25. ^ Douglas, Loudon M. (1911). The Bacillus of Long Life (1911 revised edition ed.). New York: The Knickerbocker Press. {{cite book}}: |edition= has extra text (help)
  26. ^ a b Ghaffoori H, Arif H, Musleh R, (2012) “Partial Purification of Bulgaricin Antibacterial from Lactobacilli”, 2012 2nd International Conference on Environment Science and Biotechnology IPCBEE vol.48 (2012) © (2012) IACSIT Press, Singapore available on the website: http://www.ipcbee.com/vol48/008-ICESB2012-B10007.pdf
  27. ^ Tufail, M.; Hussain, S; Malik, F; Mirza, T; Parveen, G; Shafaat S,Wajid A,Mahmood R,Channa R, Sadq A (16 October 2011). "Isolation and evaluation of antibacterial activity of bacteriocin produced by Lactobacillus bulgaricus from yogurt" (PDF). African Journal of Microbiology Research. 5 (22): 3842–3847. doi:10.5897/AJMR11.846.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  28. ^ a b Moro-García, MA (2013 Aug). "Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects". Age (Dordrecht, Netherlands). 35 (4): 1311–26. doi:10.1007/s11357-012-9434-6. ISSN 1574-4647. OCLC 60689048. PMID 22645023. Epub 2012 May 30. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: postscript (link)
  29. ^ Meyer, J (December, 2012). "Centenarians: 2010, Special Census Report" (PDF). U.S. Census Bureau. U.S. Department of Commerce Economics and Statistics Administration. {{cite web}}: Check date values in: |date= (help)
  30. ^ FDA (2013). "Label Claims for Conventional Foods and Dietary Supplements". FDA website. Retrieved 31 May 2014.{{cite web}}: CS1 maint: numeric names: authors list (link)
  31. ^ Ziarno, M. (2009). "In Vitro Cholesterol Uptake by Lactobacillus Delbrueckii Subsp. Bulgaricus Isolates" (PDF). Acta Sci. Pol., Technol. Aliment. 8 (2). Warsaw University of Life Sciences: 21–32. ISSN 1644-0730. Retrieved 31 May 2014.
  32. ^ Boyanova, L. (2008). "Anti- activity of subsp. strains: preliminary report". Letters in Applied Microbiology. 48 (5). Department of Microbiology, Medical University of Sofia, Sofia, Bulgaria: 579–584. doi:10.1111/j.1472-765X.2009.02571.x. ISSN 0266-8254. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  33. ^ Kano, Hiroshi (2013). "Oral administration of Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 suppresses inflammation by decreasing interleukin-6 responses in a murine model of atopic dermatitis". Journal of Dairy Science. 96 (6): 3525–3534. doi:10.3168/jds.2012-6514. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  34. ^ Fireman, P (2003 Mar-Apr). "Understanding asthma pathophysiology". Allergy and asthma proceedings : the official journal of regional and state allergy societies. 24 (2): 79–83. PMID 12776439. {{cite journal}}: Check date values in: |date= (help)
  35. ^ Leung, Donald Y.M. (1998 Mar). "Molecular Basis of Allergic Diseases". Molecular Genetics and Metabolism. 63 (3): 157–167. doi:10.1006/mgme.1998.2682. PMID 9608537. {{cite journal}}: Check date values in: |date= (help)
  36. ^ Hansen, I (2004 Jun). "Mediators of inflammation in the early and the late phase of allergic rhinitis". Current opinion in allergy and clinical immunology. 4 (3): 159–63. doi:10.1097/00130832-200406000-00004. PMID 15126935. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  37. ^ Katelaris, CH (2003 Jun). "Ocular allergy: implications for the clinical immunologist". Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 90 (6 Suppl 3): 23–7. doi:10.1016/S1081-1206(10)61656-0. PMID 12839109. {{cite journal}}: Check date values in: |date= (help)
  38. ^ a b c d Banerjee, Pratik (2009 Apr 27). "Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells". Gut Pathogens. 1 (1): 8. doi:10.1186/1757-4749-1-8. PMC 2680912. PMID 19397787. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: unflagged free DOI (link)
  39. ^ "CRN List of Dietary Ingredients "Grandfathered" under DSHEA" (PDF). Council for Responsible Nutrition (1998). National Nutritional Foods Association. Retrieved 31 May 2014.
  40. ^ "Title 21--Food And Drugs Chapter I--Food And Drug Administration Department Of Health And Human Services Subchapter B--Food For Human Consumption Part 131 Milk And Cream". FDA Website (21CFR131). US Food and Drug Administration (2013). Retrieved 31 May 2014.
  41. ^ United States Patent and Trademark Office (2014) Lactinex Search at USPTO website: http://tmsearch.uspto.gov/
  42. ^ Reid, G. (13 October 2003). "Potential Uses of Probiotics in Clinical Practice". Clinical Microbiology Reviews. 16 (4): 658–672. doi:10.1128/CMR.16.4.658-672.2003. PMC 207122. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  43. ^ a b c d e f g h i j k l Chen T, Dewhirst F, Izard J, Paster J, Tanner A, Wade W (2014) “Human Oral Microbiome Database” available on the electronic website: www.homd.org
  44. ^ Loesche, W (1996). "Chapter 99. Microbiology of Dental Decay and Periodontal Disease". In Baron S (ed.). Medical Microbiology (4th ed.). Galveston (TX): University of Texas Medical Branch at Galveston.
  45. ^ US Food and Drug Administration (2006). "Guidance for Industry on Complementary and Alternative Medicine Products and Their Regulation by the Food and Drug Administration" (PDF). U.S. Department of Health and Human Services Food and Drug Administration. FDA website: http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm145405.pdf. {{cite web}}: External link in |publisher= (help)
  46. ^ a b Food and Agriculture Organization of the United Nations, World Health Organization (2002) “Guidelines for the Evaluation of Probiotics” available on the FDA website: http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0282-tab-03-ref-19-joint-faowho-vol219.pdf
  47. ^ Vázquez, C (2013 Jul-Aug). "Screening in a Lactobacillus delbrueckii subsp. bulgaricus collection to select a strain able to survive to the human intestinal tract" (PDF). Nutricion hospitalaria. 28 (4): 1227–35. doi:10.3305/nh.2013.28.4.6540. ISSN 0212-1611. PMID 23889646• CODEN NUHOEQ S.V.R. 318 http://www.nutricionhospitalaria.com/pdf/6540.pdf {{cite journal}}: Check date values in: |date= (help); External link in |postscript= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)CS1 maint: postscript (link)
  48. ^ Darilmaz, D (2011). "Influence of gastrointestinal system conditions on adhesion of exopolysaccharide-producing Lactobacillus delbrueckii subsp. bulgaricus strains to caco-2 cells". Braz. arch. biol. technol. 54, n.5. Curitiba: 917–26. ISSN 1516-8913. Retrieved 31 May 2014. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=User:Martin_A_White/sandbox&oldid=611058544"